Skip to content
Screener

Alumis Inc. ALMS Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
Immunome logo
ImmunomeIMNM
$1.06M
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$40.6M
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$410.21M+87,565%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.1M+195%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.52B+693%
Enterprise value$3.49B+955%
P/S418.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Cash flows from financing activities
Proceeds from public offering of common stock, net of underwriter discounts, commissions and offering costs323,797
Proceeds from issuance of common stock upon exercise of stock options23,191
Net cash provided by financing activities346,988
Net decrease in cash, cash equivalents and restricted cash(25,780)(40,927)
Cash, cash equivalents and restricted cash at beginning of period91,053170,632
Cash, cash equivalents and restricted cash at end of period$65,273$129,705
Supplemental disclosures:

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s financing cash flow?
Alumis Inc. (ALMS) reported financing cash flow of $346.99M in Q1 2026.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Alumis Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude